Brazilian health regulator Anvisa authorizes trials for GSK-Medicago COVID vaccine
SAO PAULO (Reuters) - Brazilian health regulator Anvisa approved on Thursday the beginning of clinical trials in the country for a new COVID vaccine developed by Canada's Medicago R&D Inc and GlaxoSmithKline PLC, Anvisa said in a statement.
Anvisa said the companies were authorized to conduct phase 3 trials in the country. The companies are planning to test the new vaccines in around 30,000 people, in the U.S., Canada, Europe and Latin America. Brazil may have around 3,500 volunteers for the trials.
This will be the fifth COVID vaccine clinical trial in Brazil.
(Reporting by Eduardo Simoes and Tatiana Bautzer; Editing by Chizu Nomiyama)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.